Exact Therapeutics AS
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. … Read more
Exact Therapeutics AS - Asset Resilience Ratio
Exact Therapeutics AS (EXTX) has an Asset Resilience Ratio of 64.97% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Exact Therapeutics AS's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Exact Therapeutics AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr99.54 Million | 64.97% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr99.54 Million | 64.97% |
Asset Resilience Insights
- Very High Liquidity: Exact Therapeutics AS maintains exceptional liquid asset reserves at 64.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Exact Therapeutics AS Industry Peers by Asset Resilience Ratio
Compare Exact Therapeutics AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Exact Therapeutics AS (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Exact Therapeutics AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 64.97% | Nkr99.54 Million | Nkr153.20 Million | -10.75pp |
| 2023-12-31 | 75.72% | Nkr46.43 Million | Nkr61.32 Million | -8.38pp |
| 2022-12-31 | 84.10% | Nkr69.39 Million | Nkr82.51 Million | -4.05pp |
| 2021-12-31 | 88.15% | Nkr103.69 Million | Nkr117.63 Million | -5.50pp |
| 2020-12-31 | 93.65% | Nkr159.42 Million | Nkr170.23 Million | +7.22pp |
| 2019-12-31 | 86.43% | Nkr45.03 Million | Nkr52.10 Million | -6.35pp |
| 2018-12-31 | 92.78% | Nkr58.67 Million | Nkr63.23 Million | +17.12pp |
| 2017-12-31 | 75.66% | Nkr15.15 Million | Nkr20.02 Million | -- |